Immune cells targeted by cord blood–derived exosomes (UCB-Exo targeted immune cells)

Immune cells targeted by cord blood-derived exosomes (UCB-Exos) do not represent a single molecular target but rather a diverse population of leukocytes, including T lymphocytes, B cells, natural killer (NK) cells, and macrophages, that respond to the bioactive cargo of these extracellular vesicles. UCB-Exos are harvested from umbilical cord blood and carry a complex mixture of proteins, lipids, and microRNAs that facilitate intercellular communication and immune regulation (Source: Journal of Extracellular Vesicles, 2018). They are primarily recognized for their potent immunosuppressive and anti-inflammatory properties, often acting by inducing the differentiation of regulatory T cells (Tregs) or inhibiting the activation and proliferation of pro-inflammatory Th1 and Th17 cells (Source: Stem Cell Research & Therapy, 2019). In clinical and preclinical research, these interactions are being leveraged to develop therapies for autoimmune disorders, graft-versus-host disease (GvHD), and chronic inflammatory conditions (Source: Blood, 2021). Because this 'target' encompasses an entire cellular response network and a therapeutic modality rather than a specific protein or receptor, it is classified as a biological system or cell population in a pharmacological context.

Other names

Umbilical cord blood-derived exosome targetsUCB-Exo-responsive immune cellsCord blood exosome-mediated immune modulationUCB-EV targets

Cord blood-derived exosomes modulate immune cell activity by delivering bioactive cargo, including microRNAs (e.g., miR-146a, miR-125b) and proteins (e.g., TGF-beta, IL-10), which inhibit pro-inflammatory signaling pathways like NF-kappaB and promote the differentiation of regulatory T cells (Tregs) while suppressing effector T cell and NK cell activation (Source: Frontiers in Immunology, 2020; Stem Cell Research & Therapy, 2019).